STATResearch Highlights

Stat Plus: AACR Highlights, Chinese Biotech, and Oncology Communications

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Context and source framing

It notes that this is the final edition of that series and references a promotional incentive for STAT+ subscriptions.

The content summarizes highlights from AACR annual meeting coverage as presented by STAT News in a pop-up newsletter format.

Study design and scope

It references conference sessions and media coverage, focusing on recent topics discussed at AACR, without detailing experimental design, patient cohorts, or statistical methods within the source text.

The piece functions as a brief journalistic recap rather than a primary study report.

Key clinical and translational signals

Revolution Medicines showcased activity surrounding a new compound, RM-055, in addition to its discussed frontline pancreatic cancer data with daraxonrasib.
RM-055 is described by the CEO as part of a new class termed “catalytic inhibitors,” with the mechanism described as capable of removing a phosphate from GTP-bound RAS—i.e., the oncogenic, active form of RAS.
The report frames RM-055’s catalytic action as potentially addressing a known resistance mechanism to RAS inhibitors, specifically by reducing mutant RAS levels that can overwhelm inhibition.

Context and interpretation

The article highlights interest in mechanisms that could counteract resistance to RAS-targeted therapies, positioning RM-055 as a potential advancement in the strategy against RAS-driven cancers.
It notes that media emphasis during AACR coverage centered on frontline pancreatic cancer data for daraxonrasib, while RM-055 activity was presented as a separate, notable development.